Parallax Volatility Advisers
TVRD

Parallax Volatility Advisers’s Tvardi Therapeutics TVRD Stock Holding History

Parallax Volatility Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,083
Closed -$1.8M – 4139
2018
Q3 		$1.8M Buy
+2,083
New +$1.5M ﹤0.01% 1058
2017
Q2 		– Sell
-2,083
Closed -$1.38M – 4263
2017
Q1 		$1.38M Buy
+2,083
New +$1.11M ﹤0.01% 1011

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Parallax Volatility Advisers's TVRD Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of Tvardi Therapeutics (TVRD) in Q2 2019, closing a stake of 3,380 shares — an estimated $2.39M sold.

Parallax Volatility Advisers first reported a position in TVRD in Q2 2017 and held it in 4 quarters. The position peaked at $2.39M in Q1 2019. 126 funds tracked by Wall St. Rank hold TVRD as of Q2 2019.

  • Parallax Volatility Advisers reported no remaining Tvardi Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,380 Tvardi Therapeutics shares in Q2 2019, an estimated $2.39M.
  • Parallax Volatility Advisers first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 4 quarters.
  • Parallax Volatility Advisers's Tvardi Therapeutics position peaked at $2.39M in Q1 2019.
  • 126 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.